Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Cited In for PubMed (Select 17438479)

1.

A South African public-private partnership HIV treatment model: viability and success factors.

Igumbor J, Pascoe S, Rajap S, Townsend W, Sargent J, Darkoh E.

PLoS One. 2014 Oct 20;9(10):e110635. doi: 10.1371/journal.pone.0110635. eCollection 2014.

2.

Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis.

Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdóttir TB, Richter C, Sprangers MA, Nieuwkerk PT.

BMC Med. 2014 Aug 21;12:142. doi: 10.1186/PREACCEPT-1453408941291432.

3.

Reduced adherence to antiretroviral therapy among HIV-infected Tanzanians seeking cure from the Loliondo healer.

Thielman NM, Ostermann J, Whetten K, Whetten R, Itemba D, Maro V, Pence B, Reddy E; CHAT Research Team.

J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):e104-9. doi: 10.1097/01.qai.0000437619.23031.83.

4.

Socioeconomic factors in adherence to HIV therapy in low- and middle-income countries.

Peltzer K, Pengpid S.

J Health Popul Nutr. 2013 Jun;31(2):150-70. Review.

5.

HIV drug resistance early warning indicators in Namibia for public health action.

Jonas A, Gweshe J, Siboleka M, Deklerk M, Gawanab M, Badi A, Sumbi V, Pereko D, Blom A, Mwinga S, Jordan MR, Jerger L, Lau K, Hong SY.

PLoS One. 2013 Jun 7;8(6):e65653. doi: 10.1371/journal.pone.0065653. Print 2013.

6.

Patients' worries before starting antiretroviral therapy and their association with treatment adherence and outcomes: a prospective study in rural Uganda, 2004 - 2009.

Mayanja BN, Ekoru K, Namugenyi H, Lubega R, Mugisha JO.

BMC Res Notes. 2013 May 7;6:187. doi: 10.1186/1756-0500-6-187.

7.

Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings.

Scanlon ML, Vreeman RC.

HIV AIDS (Auckl). 2013;5:1-17. doi: 10.2147/HIV.S28912. Epub 2013 Jan 7.

8.

Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings.

Abrogoua DP, Kablan BJ, Kamenan BA, Aulagner G, N'guessan K, Zohoré C.

Patient Prefer Adherence. 2012;6:227-37. doi: 10.2147/PPA.S26507. Epub 2012 Mar 23.

9.

Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya.

Wakibi SN, Ng'ang'a ZW, Mbugua GG.

AIDS Res Ther. 2011 Dec 5;8:43. doi: 10.1186/1742-6405-8-43.

10.

Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana.

Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, Samandari T.

PLoS One. 2011 Apr 25;6(4):e18435. doi: 10.1371/journal.pone.0018435.

11.

The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR.

Infect Disord Drug Targets. 2011 Apr;11(2):124-33. Review.

12.

Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire.

Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X.

J Acquir Immune Defic Syndr. 2011 Apr;56(4):356-64. doi: 10.1097/QAI.0b013e3182084b5a.

13.

Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire.

Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-Burban S, Losina E, Freedberg KA, Danel C, Anglaret X, Yazdanpanah Y.

PLoS One. 2010 Oct 15;5(10):e13414. doi: 10.1371/journal.pone.0013414.

14.

Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa.

April MD.

Bull World Health Organ. 2010 Sep 1;88(9):703-8. doi: 10.2471/BLT.09.073049. Epub 2010 Jun 25.

15.

Population-based monitoring of HIV drug resistance in Namibia with early warning indicators.

Hong SY, Jonas A, Dumeni E, Badi A, Pereko D, Blom A, Muthiani VS, Shiningavamwe AN, Mukamba J, Andemichael G, Barbara R, Bennett DE, Jordan MR.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):27-31. doi: 10.1097/QAI.0b013e3181f5376d.

16.

Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study.

Dahab M, Charalambous S, Karstaedt AS, Fielding KL, Hamilton R, La Grange L, Churchyard GJ, Grant AD.

BMC Public Health. 2010 Jul 22;10:430. doi: 10.1186/1471-2458-10-430.

17.

Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa.

Jaquet A, Ekouevi DK, Bashi J, Aboubakrine M, Messou E, Maiga M, Traore HA, Zannou MD, Guehi C, Ba-Gomis FO, Minga A, Allou G, Eholie SP, Bissagnene E, Sasco AJ, Dabis F.

Addiction. 2010 Aug;105(8):1416-21. doi: 10.1111/j.1360-0443.2010.02978.x. Epub 2010 Jun 7.

18.

Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting.

Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, Jacobson M.

AIDS Care. 2010 Mar;22(3):381-9. doi: 10.1080/09540120903193708.

19.

Explaining adherence success in sub-Saharan Africa: an ethnographic study.

Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, Chalamilla G, Bangsberg DR.

PLoS Med. 2009 Jan 27;6(1):e11. doi: 10.1371/journal.pmed.1000011.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk